Exhibit 99.2
--------------------------------------------------------------------------------
TUTOGEN MEDICAL AND MENTOR ENTER INTO EXCLUSIVE
DISTRIBUTION AGREEMENT FOR BREAST RECONSTRUCTION MARKET
--------------------------------------------------------------------------------
MENTOR WILL HAVE THE EXCLUSIVE NORTH AMERICAN RIGHTS FOR TUTOPLAST DERMIS
FOR IMMEDIATE RELEASE
Contacts:
L. Xxxxxx Xxxxxxxx, CFO Lytham Partners, LLC
Tutogen Medical, Inc. Institutional: Xxx Xxxx
000-000-0000 Retail: Xxx Xxxxxx
xxxxxxxxx@xxxxxxx.xxx 602-889-9700
ALACHUA, FLORIDA - JUNE 29, 2006 - Tutogen Medical, Inc., (AMEX: TTG), a leading
manufacturer of sterile biological implant products made from human (allograft)
and animal (xenograft) tissue, today announced that it has entered into a
distribution agreement with Mentor Corporation, a leader in the breast implant
and aesthetic product markets. Mentor will have the exclusive North American
rights for the use of Tutoplast Dermis in the dermatology and plastic surgery
markets for breast reconstruction. Tutogen will be receiving an upfront payment
in consideration for these distribution rights.
Xxx Xxxxx, Chief Executive Officer of Tutogen, commented, "We are excited to be
partnering with Mentor in this important market. The Tutoplast processed grafts
complement Mentor's implant products for breast reconstruction following
mastectomy or injury. We are pleased to be helping women regain their natural
profile and confidence following these difficult events."
ABOUT TUTOGEN MEDICAL, INC. Tutogen Medical, Inc. manufactures sterile
biological implant products made from human (allograft) and animal (xenograft)
tissue. Tutogen utilizes its Tutoplast Process(R) of tissue preservation and
viral inactivation to manufacture and deliver sterile bio-implants used in
spinal/trauma, urology, dental, ophthalmology, and general surgery procedures.
The Company's Tutoplast(R) products are sold and distributed worldwide by Zimmer
Spine and Zimmer Dental, subsidiaries of Xxxxxx Holdings, Inc. the Mentor
Corporation, IOP, Inc. and through independent distributors and subsidiaries in
the U.S. and Germany. For more information, visit the Company's Web site at
XXXX://XXX.XXXXXXX.XXX.
FORWARD-LOOKING STATEMENT DISCLAIMER: CERTAIN STATEMENTS IN THIS NEWS RELEASE
ARE FORWARD-LOOKING AND ARE MADE PURSUANT TO THE SAFE HARBOR PROVISIONS OF THE
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE RISKS
AND UNCERTAINTIES, WHICH MAY DIFFER MATERIALLY FROM THOSE SET FORTH IN THESE
STATEMENTS, INCLUDING THE STATUS OF THE COMPANY'S LISTING ON THE AMERICAN STOCK
EXCHANGE AND THE ANTICIPATED TIMING FOR RESTATEMENT OF THE COMPANY'S FINANCIAL
STATEMENTS. FORWARD-LOOKING STATEMENTS ARE BASED ON MANAGEMENT'S CURRENT
EXPECTATIONS AND ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE
ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE SET FORTH OR IMPLIED BY
FORWARD-LOOKING STATEMENTS. THESE AND OTHER RISKS ARE IDENTIFIED IN THE
COMPANY'S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION, INCLUDING THE
COMPANY'S ANNUAL REPORT ON FORM 10-K FOR THE FISCAL YEAR ENDED SEPTEMBER 30,
2005. ALL INFORMATION IN THIS PRESS RELEASE IS AS OF THE DATE HEREOF, AND THE
COMPANY UNDERTAKES NO DUTY TO UPDATE THIS INFORMATION UNLESS REQUIRED BY LAW.
